Transosseous Route for CT Fluoroscopy-Guided Radiofrequency Ablation of XXXX .

@entity1 @entity174 @entity548 @entity5 @entity55 @entity2 @entity9
PURPOSE: To retrospectively evaluate radiofrequency (RF) ablation of @entity2 performed via the transosseous approach. MATERIALS AND METHODS: Twelve @entity2 (mean diameter, 1.0 cm; range, 0.4-1.6 cm) in 12 @entity1 were treated by RF ablation via a transscapular and/or transrib route with the use of a bone biopsy needle under computed tomographic fluoroscopy guidance. Therapeutic outcomes evaluated included feasibility, safety, and local efficacy. Complications were assessed based on the National @entity5 Institute Common Terminology Criteria for Adverse Events, version 4.0. RESULTS: The transosseous route was successfully employed in all @entity1 , and the electrode was successfully advanced into all @entity5 with this approach. The mean distance of penetrated bone was 0.57 cm (range, 0.19-1.16 cm). Complications occurred in eight RF ablation sessions, including six grade 1 events (two cases of pneumothorax and one case each of asymptomatic @entity174 6 mo after treatment, @entity9 , @entity548 , and hemothorax), two grade 2 events ( @entity55 and high fever), and one grade 3 event (pneumothorax requiring pleurodesis). No adverse events of grade >=  4 occurred. The mean and median @entity5 follow-up periods were 19.5 and 15.2 mo (range, 3.0-41.5 mo). Local progression occurred in two cases at 3 and 12 mo after treatment and was successfully treated with a second RF ablation procedure. The technique efficacy rates were 91.7% at 6 mo, 81.5% at 1 y, and 81.5% at 2 y. CONCLUSIONS: The transosseous approach was feasible in computed tomographic fluoroscopy-guided RF ablation of select @entity2 when no other option was available.
